Potential of liraglutide in the treatment of patients with type 2 diabetes
Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-02-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/potential-of-liraglutide-in-the-treatment-of-patients-with-type-2-diab-a2835 |